TAKEDA PHARMACEUTICAL CO LTD's ticker is TAK and the CUSIP is 874060205. A total of 273 filers reported holding TAKEDA PHARMACEUTICAL CO LTD in Q3 2022. The put-call ratio across all filers is 0.29 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $560 | +2.0% | 36,284 | +1.2% | 0.01% | +8.3% |
| Q2 2023 | $549 | -14.2% | 35,863 | -7.6% | 0.01% | -20.0% |
| Q1 2023 | $640 | -2.9% | 38,798 | -8.2% | 0.02% | -6.2% |
| Q4 2022 | $659 | -99.9% | 42,279 | +7.0% | 0.02% | +14.3% |
| Q3 2022 | $513,000 | +6.4% | 39,519 | +15.2% | 0.01% | +16.7% |
| Q2 2022 | $482,000 | -3.0% | 34,290 | -1.2% | 0.01% | +9.1% |
| Q1 2022 | $497,000 | +2.9% | 34,720 | -2.1% | 0.01% | +10.0% |
| Q4 2021 | $483,000 | -16.4% | 35,460 | +0.5% | 0.01% | -28.6% |
| Q3 2021 | $578,000 | +2.7% | 35,290 | +5.6% | 0.01% | +7.7% |
| Q2 2021 | $563,000 | -7.4% | 33,430 | +0.4% | 0.01% | -13.3% |
| Q1 2021 | $608,000 | -23.3% | 33,300 | -23.5% | 0.02% | -25.0% |
| Q4 2020 | $793,000 | +11.2% | 43,550 | +8.9% | 0.02% | 0.0% |
| Q3 2020 | $713,000 | -3.4% | 39,990 | -2.8% | 0.02% | -9.1% |
| Q2 2020 | $738,000 | – | 41,150 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Glenview Capital Management | 16,104,222 | $294,063,000 | 4.98% |
| GMT CAPITAL CORP | 2,468,695 | $45,078,000 | 3.31% |
| MANAGED ASSET PORTFOLIOS, LLC | 1,065,756 | $19,461,000 | 3.13% |
| Blackcrane Capital, LLC | 14,571 | $1,723,000 | 2.72% |
| BFAM Partners (Cayman) Ltd | 328,690 | $6,002,000 | 2.36% |
| Paulson & Co. | 4,727,415 | $86,323,000 | 1.98% |
| Mondrian Investment Partners LTD | 3,510,404 | $59,677,000 | 1.28% |
| Lumbard & Kellner, LLC | 135,550 | $2,264,000 | 0.80% |
| DAVIDSON INVESTMENT ADVISORS | 500,203 | $9,134,000 | 0.78% |
| TFG Asset Management GP Ltd | 589,390 | $10,762,000 | 0.77% |